As a devoted partner, we develop and publish the scientific evidence to support utility of our tests. We work directly with health plans to help ensure patients have access to our services. Our two certified laboratories meet and exceed the standards put forth by the largest regulating bodies.
VeriStrat® is blood-based proteomic test that provides predictive and prognostic information for patients with non-small cell lung cancer (NSCLC).
GeneStrat® is a blood-based genomic portfolio that provides guideline-recommended actionable mutations for patients with NSCLC to expedite time to treatment.
Nodify XL2® is a blood-based lung nodule test that helps identify patients with a lower risk of malignancy that can be safely monitored with follow-up CT scans, alleviating patient anxiety and avoiding unnecessary invasive diagnostic procedures.
We operate two world-class, accredited clinical laboratories that support the standards put forth by the largest regulating bodies.
We understand the financial stresses that health issues can place on patients. That's why we created a financial assistance program for patients with financial responsibility to assist in providing affordable care.